{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:05:52Z","timestamp":1793023552196,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,10,28]]},"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Fluoroquinolone-associated tendon ruptures are a recognised complication, but other severe collagen-associated adverse events may also be possible. Our objectives were to confirm the association of fluoroquinolones and tendon rupture, to clarify the potential association of fluoroquinolones and retinal detachment, and to test for a potentially lethal association between fluoroquinolones and aortic aneurysms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Population-based longitudinal cohort study in Ontario, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Older adults turning 65\u2005years between April 1 1997 and March 31 2012 were followed until primary outcome, death, or end of follow-up (March 31 2014). Fluoroquinolone prescriptions were measured as a time-varying covariate, with patients considered at risk during and for 30\u2005days following a treatment course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measures<\/jats:title>\n                    <jats:p>Severe collagen-associated adverse events defined as tendon ruptures, retinal detachments and aortic aneurysms diagnosed in hospital and emergency departments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 1\u2005744\u2005360 eligible patients, 657\u2005950 (38%) received at least one fluoroquinolone during follow-up, amounting to 22\u2005380\u2005515 days of treatment. The patients experienced 37\u2005338 (2.1%) tendon ruptures, 3246 (0.2%) retinal detachments, and 18\u2005391 (1.1%) aortic aneurysms. Severe collagen-associated adverse events were more common during fluoroquinolone treatment than control periods, including tendon ruptures (0.82 vs 0.26\/100-person years, p&lt;0.001), retinal detachments (0.03 vs 0.02\/100-person-years, p=0.003) and aortic aneurysms (0.35 vs 0.13\/100-person-years, p&lt;0.001). Current fluoroquinolones were associated with an increased hazard of tendon rupture (HR 3.13, 95% CI 2.98 to 3.28; adjusted HR 2.40, 95% CI 2.24 to 2.57) and an increased hazard of aortic aneurysms (HR 2.72, 95% CI 2.53 to 2.93; adjusted HR2.24, 95% CI 2.02 to 2.49) that were substantially greater in magnitude than the association of these outcomes with amoxicillin. The hazard of retinal detachment was marginal (HR 1.28, 95% CI 0.99 to 1.65; adjusted HR 1.47, 95% CI 1.08 to 2.00) and not greater in magnitude than that observed with amoxicillin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fluoroquinolones are associated with subsequent tendon ruptures and may also contribute to aortic aneurysms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010077","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T21:54:11Z","timestamp":1447883651000},"page":"e010077","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":203,"title":["Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study"],"prefix":"10.1136","volume":"5","author":[{"given":"Nick","family":"Daneman","sequence":"first","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A","family":"Redelmeier","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"2025121512023820000_5.11.e010077.1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.3717"},{"key":"2025121512023820000_5.11.e010077.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.09.015"},{"key":"2025121512023820000_5.11.e010077.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.02.028"},{"key":"2025121512023820000_5.11.e010077.4","unstructured":"U.S. Food and Drug Administration Information for Healthcare Professionals Black Box Warning Fluoroquinolones and Tendinitis and Tendon Rupture. 7-8-0008. 1-30-2014."},{"key":"2025121512023820000_5.11.e010077.5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.amjmed.2012.05.027","article-title":"Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders","volume":"125","author":"Wise","year":"2012","journal-title":"Am J Med"},{"key":"2025121512023820000_5.11.e010077.6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/11594770-000000000-00000","article-title":"Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples","volume":"35","author":"Wahl","year":"2012","journal-title":"Drug Saf"},{"key":"2025121512023820000_5.11.e010077.7","doi-asserted-by":"publisher","DOI":"10.1007\/s002040000203"},{"key":"2025121512023820000_5.11.e010077.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.009"},{"key":"2025121512023820000_5.11.e010077.9","doi-asserted-by":"publisher","DOI":"10.1002\/jor.21196"},{"key":"2025121512023820000_5.11.e010077.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.383"},{"key":"2025121512023820000_5.11.e010077.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280500"},{"key":"2025121512023820000_5.11.e010077.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1877382601306010001","article-title":"The role of collagen in the aorta's structure","volume":"6","author":"Berillis","year":"2013","journal-title":"Open Circulation Vascular J"},{"key":"2025121512023820000_5.11.e010077.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.08.003"},{"key":"2025121512023820000_5.11.e010077.14","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"2025121512023820000_5.11.e010077.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"2025121512023820000_5.11.e010077.16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamainternmed.2013.3029","article-title":"Prolonged antibiotic treatment in long-term care: role of the prescriber","volume":"173","author":"Daneman","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2025121512023820000_5.11.e010077.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055191"},{"key":"2025121512023820000_5.11.e010077.18","doi-asserted-by":"publisher","DOI":"10.1086\/375078"},{"key":"2025121512023820000_5.11.e010077.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.01.043"},{"key":"2025121512023820000_5.11.e010077.20","doi-asserted-by":"publisher","DOI":"10.4065\/79.2.176"},{"key":"2025121512023820000_5.11.e010077.21","unstructured":"Canadian Health Information Management Association. Reabstraction Study of the Ontario Case Costing Facilities: For Fiscal Years 2002\/2003 and 2003\/2004. 2005."},{"key":"2025121512023820000_5.11.e010077.22","unstructured":"NACRS CIHI Data Quality Study of Ontario Emergency Department Visits for 2004\u20132005\u2014Executive Summary. Canadian Institute for Health Information, 2007."},{"key":"2025121512023820000_5.11.e010077.23","doi-asserted-by":"crossref","unstructured":"Redelmeier DA , Thiruchelvam D , Daneman N . Introducing a methodology for estimating duration of surgery in health services research. J Clin Epidemiol 2008. doi:10.1016\/j.jclinepi.2007.10.015","DOI":"10.1016\/j.jclinepi.2007.10.015"},{"key":"2025121512023820000_5.11.e010077.24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2098"},{"key":"2025121512023820000_5.11.e010077.25","unstructured":"Allison PD . Survival Analysis Using SAS a Practical Guide. 2015."},{"key":"2025121512023820000_5.11.e010077.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7349.1306"},{"key":"2025121512023820000_5.11.e010077.27","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.15.1801"},{"key":"2025121512023820000_5.11.e010077.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.11.014"},{"key":"2025121512023820000_5.11.e010077.29","first-page":"759","article-title":"Mutation in collagen II alpha 1 isoforms delineates Stickler and Wagner syndrome phenotypes","volume":"19","author":"Tran-Viet","year":"2013","journal-title":"Mol Vis"},{"key":"2025121512023820000_5.11.e010077.30","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.123839"},{"key":"2025121512023820000_5.11.e010077.31","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.8.972"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T20:02:45Z","timestamp":1765828965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,18]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/bmjopen-2015-010077"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010077","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}